Prior authorization delays in insurance are impacting cancer care delivery, prompting calls for reform to eliminate administrative barriers and improve patient outcomes.

Research reveals immune checkpoint inhibitors improve cancer survival rates but widen insurance-based disparities. Expanding health coverage may mitigate gaps in treatment outcomes.

Research reveals that survival disparities by insurance coverage have widened after immune checkpoint inhibitors approval for stage IV cancers, urging policy action to improve access and affordability.

Former President Joe Biden diagnosed with aggressive prostate cancer that has spread to bones. Hormone-sensitive, high Gleason score cancer poses treatment challenges but remains manageable with hormone therapy. Biden's diagnosis brings attention to advanced prostate cancer treatment and related health policy discussions.

Atrium Health Levine Cancer's Financial Toxicity Tumor Board mitigates financial distress among cancer patients, improving treatment outcomes and reducing insurance claim denials. A five-year study highlights its efficacy and suggests it as a best practice for cancer centers.